Key opportunities in the Bronchiectasis clinical trials market include leveraging comprehensive data on trial distribution by region, identifying cost-effective trial locations, assessing trial ...

Sep. 24—(StatePoint) Getting the correct treatment for bronchiectasis, a chronic lung condition affecting 350,000 to 500,000 adults nationwide, is necessary to slow disease progression and help ...

Bronchiectasis is a chronic condition of the respiratory system, in which there is abnormal widening of the airways due to an initial damaging factor. This in turn reduces the ability of the bronchi ...

Dublin, Dec. 09, 2024 (GLOBE NEWSWIRE) -- The "Bronchiectasis - Market Insight, Epidemiology and Market Forecast - 2034" report has been added to ResearchAndMarkets.com's offering. This report ...

Bronchiectasis is a chronic condition of the respiratory system that is due to abnormal widening of the airways as a consequence of an initial damaging factor. The bronchi, located between the trachea ...

While bronchiectasis is an old condition, it is only in the last decade that there have been major strides in our understanding of this disease and its treatment. Recent evidence has shown that the ...

A Prescription Drug User Fee Act target date of August 12, 2025 has been set for the application. The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application (NDA) ...

Dr Metersky provides his closing thoughts, highlighting key points of emphasis surrounding bronchiectasis care and the future of its treatment landscape. Pamela J. McShane, MD, explores the clinical ...

Please provide your email address to receive an email when new articles are posted on . Indigenous ethnicity and new abnormal auscultatory signs raised the odds for symptom resolution after antibiotic ...

PHILADELPHIA (WPVI) -- A cough can be a mild irritant or a signal of something more serious, especially when it stretches for weeks on end. When you have a cough that lasts for some time it is ...

Bronchiectasis hospitalizations have higher mortality and costs than COPD and asthma, with a median stay of 5 days and costs of $50,393. During the COVID-19 pandemic, bronchiectasis hospitalizations ...

BRONCHIECTASIS is protean in its expressions as it is sometimes obscure in its origin. The clinical picture varies in individual patients, but common to the severer cases is a history of harassing, ...